Introducing ISMP’s New Targeted Medication Safety Best Practices for Community Pharmacy: 2023-2024

Join ISMP for a complimentary webinar as we seek to inspire and mobilize practitioners from around the US in the national adoption of specific consensus-based safe practices selected to reduce or eliminate repetitive medication safety issues in community pharmacies that continue to cause harmful or fatal errors to patients.

During this webinar, learn about ISMP’s new Targeted Medication Safety Best Practices for Community Pharmacy and why they were selected for national action. Don’t miss this opportunity to join this important call and align your safety practices.

Learning Objectives

1. Cite the three new best practices from the ISMP Targeted Medication Safety Best Practices for Community Pharmacy.

2. Describe the medication errors that each of these new best practices were designed to prevent.

3. Describe recommended strategies related to ISMP Targeted Medication Safety Best Practices for Community Pharmacy. 

Speaker

Michael J. Gaunt, PharmD, Senior Manager, Error Reporting Programs, ISMP

CE Accreditation

Released: April 28, 2023
Expiration: April 27, 2025

^{Pharmacists and Pharmacy Technicians
This CE activity is jointly provided by ProCE, LLC and the Institute for Safe Medication Practices (ISMP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-23-001-H05-P/T has been assigned to this live knowledge-based CE activity (initial release date 1/31/2023). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.}

This activity is supported by Novartis, Name Creation & Regulatory Strategy.